"at this point we attribute the early favorable re
Post# of 72440
(Total Views: 165)
Posted On: 01/17/2017 6:41:45 PM
"at this point we attribute the early favorable results to Brilacidin’s robust anti-inflammatory therapeutic profile."
We're not getting any statements like "possible anti-inflammatory action" any more. They are stating it as FACT.
What do you think this means for the Brilacidin-OM trial? I think it probably means very good things.
We're not getting any statements like "possible anti-inflammatory action" any more. They are stating it as FACT.
What do you think this means for the Brilacidin-OM trial? I think it probably means very good things.
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼